Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
Year: 2022
Type: article
Source: Blood
Authors: Hongtao Liu, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher S. Hourigan, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Wendy Stock
Institutions: University of Chicago, National Cancer Institute, Moffitt Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Illinois CancerCare, University of California Davis Medical Center, University of California, Davis, University Health Network, Princess Margaret Cancer Centre, VCU Massey Comprehensive Cancer Center, Yale Cancer Center, Yale University, University of Kentucky, National Institutes of Health, National Heart, Lung, and Blood Institute, Dartmouth–Hitchcock Medical Center, University of Wisconsin Carbone Cancer Center, Thomas Jefferson University Hospital, City Of Hope National Medical Center, Beckman Research Institute, University of California San Diego, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Kansas, The University of Texas Southwestern Medical Center, University of Chicago Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310108905